Alemtuzumab-based Therapy for Secondary Malignant Histiocytosis Arising from Pre-B-ALL

This report is the first to highlight the role of alemtuzumab, an anti-CD52 monoclonal antibody, in clonal disorders originating from transdifferentiation. • The alemtuzumab-based regimen should be reserved only for carefully selected allogeneic transplant patients.
Source: Leukemia Research Reports - Category: Hematology Source Type: research